missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Melford 17-AAG
17-AAG (17-Allylamino-17-demethoxygeldanamycin) is a synthetic derivative of geldanamycin. Like geldanamycin, 17-AAG is recognized for its role as an inhibitor of heat shock protein 90 (Hsp90), a molecular chaperone involved in protein folding and stabilization.
121.00€ - 201.00€
| Product Code | Brand | Quantity | Price | Quantity & Availability | |||||
|---|---|---|---|---|---|---|---|---|---|
| Product Code | Brand | Quantity | Price | Quantity & Availability | |||||
|
30017965
|
Melford
A20045-0.0005 |
500 μg |
121.00€
500µg |
Estimated Shipment: 02-12-2024
Log in to see stock. |
|||||
|
30017966
|
Melford
A20045-0.001 |
1 mg |
201.00€
1mg |
Estimated Shipment: 02-12-2024
Log in to see stock. |
|||||
Description
17-AAG (17-Allylamino-17-demethoxygeldanamycin) is a synthetic derivative of geldanamycin. Like geldanamycin, 17-AAG is recognized for its role as an inhibitor of heat shock protein 90 (Hsp90), a molecular chaperone involved in protein folding and stabilization.
17-AAG (17-Allylamino-17-demethoxygeldanamycin) is a synthetic derivative of geldanamycin. Like geldanamycin, 17-AAG is recognized for its role as an inhibitor of heat shock protein 90 (Hsp90), a molecular chaperone involved in protein folding and stabilization.
It is often used as a tool to study Hsp90-dependent processes. By inhibiting Hsp90, 17-AAG impacts the stability and function of various client proteins, many of which are involved in critical cellular processes, including signal transduction and cell cycle regulation. Similar to geldanamycin, 17-AAG is particularly relevant in cancer research, as Hsp90 is often crucial for the stability of oncoproteins.
Researchers use 17-AAG to explore the molecular mechanisms of Hsp90 inhibition, with potential applications in understanding cancer biology and developing therapeutic strategies.
Specifications
| 75747-14-7 | |
| C31H43N3O8 |